Cart
sales@molnova.com
Home - Products - Autophagy - CXCR - WZ811

WZ811

CAS No. 55778-02-4

WZ811( WZ811 | WZ-811 | WZ 811 )

Catalog No. M15027 CAS No. 55778-02-4

WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 43 In Stock
10MG 55 In Stock
25MG 104 In Stock
50MG 167 In Stock
100MG 233 In Stock
200MG 302 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    WZ811
  • Note
    Research use only, not for human use.
  • Brief Description
    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
  • Description
    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    WZ811 | WZ-811 | WZ 811
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR4
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    55778-02-4
  • Formula Weight
    290.36
  • Molecular Formula
    C18H18N4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 30 mg/mL (103.32 mM)
  • SMILES
    C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1
  • Chemical Name
    N,N'-(1,4-phenylenebis(methylene))bis(pyridin-2-amine)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhan W, et al. J Med Chem, 2007, 50(23), 5655-5664.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Ulocuplumab

    Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.

  • CXCR7 antagonist-1

    CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7.

  • AD80

    AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.

Sign In Join Free